223 related articles for article (PubMed ID: 6431334)
1. [Chemotherapy in advanced forms of carcinoma of the ovary].
Calciati A; Clerico M; Donadio M; Giaccone G
Minerva Ginecol; 1984 Apr; 36(4):195-8. PubMed ID: 6431334
[No Abstract] [Full Text] [Related]
2. [Chemotherapy of epithelial ovarian carcinoma].
Bruntsch U; Gallmeier WM
MMW Munch Med Wochenschr; 1983 Nov; 125(44):993-5. PubMed ID: 6417517
[No Abstract] [Full Text] [Related]
3. [Chemotherapy in 143 advanced epithelial cancers of the ovary. Experience at the Hôtel-Dieu of Quebec and Hôpital Saint-Antoine (Paris)].
de Gramont A; Drolet Y; Louvet C; Dray C; Krulik M; Pigné A; Lavoie A; Painchaud M; Blouin R; Tessier C
J Gynecol Obstet Biol Reprod (Paris); 1986; 15(1):105-9. PubMed ID: 3084619
[TBL] [Abstract][Full Text] [Related]
4. Hexamethylmelamine-CAF (cyclophosphamide, methotrexate, and 5-FU) and cisplatin-CAF in refractory ovarian cancer.
Sessa C; D'Incalci M; Valente I; Bolis G; Colombo N; Mangioni C
Cancer Treat Rep; 1982 May; 66(5):1233-4. PubMed ID: 6805951
[No Abstract] [Full Text] [Related]
5. Randomized trial of initial therapy with melphalan versus cisplatin-based combination chemotherapy in patients with advanced ovarian carcinoma: initial and long term results--Eastern Cooperative Oncology Group Study E2878.
Wadler S; Yeap B; Vogl S; Carbone P
Cancer; 1996 Feb; 77(4):733-42. PubMed ID: 8616766
[TBL] [Abstract][Full Text] [Related]
6. [Chemotherapy of epithelial ovarian cancer: CHexUP versus thio-tepa].
Wu BZ
Zhonghua Fu Chan Ke Za Zhi; 1987 Jan; 22(1):5-8, 61. PubMed ID: 3109851
[No Abstract] [Full Text] [Related]
7. Hexa-CAF combination chemotherapy and other multiple-drug regimens in advanced ovarian carcinoma: present and future.
Neijt JP; van Lindert AC; Vendrik CP; Roozendaal KJ; Struyvenberg A; Pinedo HM
Neth J Med; 1979; 22(2):38-44. PubMed ID: 107464
[No Abstract] [Full Text] [Related]
8. The application of dose intensity to problems in chemotherapy of ovarian and endometrial cancer.
Levin L; Hryniuk W
Semin Oncol; 1987 Dec; 14(4 Suppl 4):12-9. PubMed ID: 3120317
[TBL] [Abstract][Full Text] [Related]
9. The case for combination chemotherapy in the treatment of advanced ovarian cancer.
Ozols RF
J Clin Oncol; 1985 Nov; 3(11):1445-7. PubMed ID: 3932603
[No Abstract] [Full Text] [Related]
10. Modulation and intensification of a cyclophosphamide, hexamethylmelamine, doxorubicin, and cisplatin ovarian cancer regimen.
Bruckner HW; Cohen CJ; Feuer E; Holland JF
Obstet Gynecol; 1989 Mar; 73(3 Pt 1):349-56. PubMed ID: 2492648
[TBL] [Abstract][Full Text] [Related]
11. [Treatment of advanced ovarian carcinoma with cyclophosphamide, adriamycin and cisplatin: evaluation of the therapeutic response and analysis of the collateral effects].
Facchini V; Gadducci A; Ceccarelli P; Dell'Arciprete T; Del Bravo B; Bartolini T; Fioretti P
Ann Ostet Ginecol Med Perinat; 1986; 107(6):359-68. PubMed ID: 3566043
[No Abstract] [Full Text] [Related]
12. Improved therapy with cisplatin regimens for patients with ovarian carcinoma (FIGO III and IV) as measured by surgical end-staging (second-look surgery)--the mount sinai experience.
Cohen CJ; Bruckner HW; Goldberg JD; Holland JF
Clin Obstet Gynaecol; 1983 Aug; 10(2):307-24. PubMed ID: 6413114
[No Abstract] [Full Text] [Related]
13. [High-dose chemotherapy in ovarian adenocarcinoma].
Lotz JP; Lhommé C; Pautier P; Couteau C; Gligorov J; Alexandre J; Selle F; Izrael V; Maraninchi D; Viens P
Bull Cancer; 2000 Jan; 87(1):63-9. PubMed ID: 10673633
[No Abstract] [Full Text] [Related]
14. [The potentials of combined chemotherapy in disseminated ovarian cancer].
Gorbunova VA; Perevodchikova NI; Kozachenko VP; Ryzhakov VM; Marenich AF; Zhordania KI
Akush Ginekol (Mosk); 1991 Feb; (2):54-7. PubMed ID: 1907433
[No Abstract] [Full Text] [Related]
15. [Combined modality for recurrent and disseminated ovarian cancer--CAPF combination chemotherapy and second-look operation].
Inagaki J; Ogawa M; Horikoshi N; Ezaki K; Inoue K; Aiba K; Komyo M; Miyamoto H; Ikeda K; Kubo H
Gan No Rinsho; 1983 Aug; 29(10):1291-5. PubMed ID: 6685195
[TBL] [Abstract][Full Text] [Related]
16. [Controlled prospective study of chemotherapy in advanced ovarian cancer--cyclophosphamide monochemotherapy versus polychemotherapy with adriamycin, cyclophosphamide, 5-fluorouracil and methotrexate].
Chylak V; Kolarić K; Krusić J
Lijec Vjesn; 1987 Jun; 109(6):230-4. PubMed ID: 3309515
[No Abstract] [Full Text] [Related]
17. Chemotherapy of ovarian cancer.
Ozols RF; Young RC
Semin Oncol; 1984 Sep; 11(3):251-63. PubMed ID: 6435250
[No Abstract] [Full Text] [Related]
18. Chemotherapy in advanced ovarian carcinoma: current standards of care based on randomized trials.
Thigpen T; Vance R; Puneky L; Khansur T
Gynecol Oncol; 1994 Dec; 55(3 Pt 2):S97-107. PubMed ID: 7835816
[TBL] [Abstract][Full Text] [Related]
19. Cisplatin-MECY (methotrexate-leucovorin rescue plus cyclophosphamide) versus cisplatin-CHAD (cyclophosphamide, hexamethylmelamine, doxorubicin, and cisplatin) as initial chemotherapy in stage III-IV ovarian adenocarcinoma.
Barlow JJ; Lele SB
Cancer Treat Rep; 1984 Dec; 68(12):1433-8. PubMed ID: 6439408
[TBL] [Abstract][Full Text] [Related]
20. Ovarian cancer: what is poor prognosis disease?
Cohen MH
J Clin Oncol; 1990 Jul; 8(7):1287-8. PubMed ID: 2113572
[No Abstract] [Full Text] [Related]
[Next] [New Search]